Tracy B. Taylor

Wichita Technology Ventures LLC (WTV) is a venture capital subsidiary of Wichita Technology Corp. founded in 1994. The firm is headquartered in Wichita, Kansas.

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ.

Founded in 1987, the Kansas Technology Enterprise Corporation is a private/public partnership established by the state of Kansas to promote technology based economic development. They are located in Topeka, Kansas

Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline.

Enterprise Center of Johnson County/Venture Capital/ is a subsidiary of Enterprise Center of Johnson County founded in 1994. The firm headquartered in Fairway, Kansas.

Townsend Capital LLC invests in commercial real estate and energy sector. It specializes in the structuring and placement of tax advantaged investments in real estate, and oil and natural gas exploration for third party investors. Townsend Capital maintains real estate portfolios that includes a mix of office, warehouse, industrial, research, institutional and healthcare space. The company was founded by Dennis Townsend in 1975 and is headquartered in Hunt Valley, MD.